$273.91
+3.82
(+1.41%)▲
Danaher Corporation is a global science and technology company that designs, manufactures, and markets a range of products and services.
0.89%
Downside
Day's Volatility :2.24%
Upside
1.36%
33.73%
Downside
52 Weeks Volatility :34.31%
Upside
0.87%
Period | Danaher Corp. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 9.53% | 6.5% | 5.9% |
6 Months | 15.92% | 7.1% | 10.4% |
1 Year | 1.97% | 9.8% | 18.2% |
3 Years | -6.92% | 14.2% | 22.1% |
Market Capitalization | 191.9B |
Book Value | $68.92 |
Dividend Share | 1.05 |
Dividend Yield | 0.41% |
Earnings Per Share (EPS) | 5.45 |
PE Ratio | 48.76 |
PEG Ratio | 3.13 |
Wall Street Target Price | 260.9 |
Profit Margin | 17.83% |
Operating Margin TTM | 20.34% |
Return On Assets TTM | 3.96% |
Return On Equity TTM | 7.98% |
Revenue TTM | 23.6B |
Revenue Per Share TTM | 31.88 |
Quarterly Revenue Growth YOY | -2.9000000000000004% |
Gross Profit TTM | 18.9B |
EBITDA | 7.4B |
Diluted Eps TTM | 5.45 |
Quarterly Earnings Growth YOY | -0.18 |
EPS Estimate Current Year | 6.99 |
EPS Estimate Next Year | 8.02 |
EPS Estimate Current Quarter | 1.57 |
EPS Estimate Next Quarter | 1.69 |
What analysts predicted
Downside of 4.75%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 19.9B | ↑ 8.53% |
Net Income | 2.7B | ↑ 6.37% |
Net Profit Margin | 13.33% | ↓ 0.27% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 17.9B | ↓ 9.96% |
Net Income | 3.0B | ↑ 13.48% |
Net Profit Margin | 16.8% | ↑ 3.47% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 22.3B | ↑ 24.41% |
Net Income | 3.6B | ↑ 21.2% |
Net Profit Margin | 16.36% | ↓ 0.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 29.5B | ↑ 32.17% |
Net Income | 6.4B | ↑ 76.44% |
Net Profit Margin | 21.84% | ↑ 5.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 31.5B | ↑ 6.85% |
Net Income | 7.2B | ↑ 12.06% |
Net Profit Margin | 22.91% | ↑ 1.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 23.9B | ↓ 24.09% |
Net Income | 4.7B | ↓ 34.21% |
Net Profit Margin | 19.85% | ↓ 3.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.2B | ↓ 14.36% |
Net Income | 1.5B | ↓ 35.04% |
Net Profit Margin | 20.23% | ↓ 6.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.2B | ↓ 0.14% |
Net Income | 1.1B | ↓ 23.72% |
Net Profit Margin | 15.45% | ↓ 4.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.9B | ↓ 3.97% |
Net Income | 1.1B | ↑ 2.08% |
Net Profit Margin | 16.43% | ↑ 0.98% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7B | ↓ 60.82% |
Net Income | 1.1B | ↓ 4.43% |
Net Profit Margin | 40.07% | ↑ 23.64% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.8B | ↑ 115.22% |
Net Income | 1.1B | ↑ 0.83% |
Net Profit Margin | 18.77% | ↓ 21.3% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.7B | ↓ 0.91% |
Net Income | 907.0M | ↓ 16.64% |
Net Profit Margin | 15.79% | ↓ 2.98% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 47.8B | ↑ 2.54% |
Total Liabilities | 19.6B | ↓ 3.33% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 62.1B | ↑ 29.79% |
Total Liabilities | 31.8B | ↑ 62.2% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 76.2B | ↑ 22.68% |
Total Liabilities | 36.4B | ↑ 14.42% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 83.2B | ↑ 9.22% |
Total Liabilities | 38.0B | ↑ 4.46% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 84.4B | ↑ 1.4% |
Total Liabilities | 34.3B | ↓ 9.86% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 84.5B | ↑ 0.16% |
Total Liabilities | 31.0B | ↓ 9.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 85.0B | ↑ 0.82% |
Total Liabilities | 33.6B | ↓ 2.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 84.9B | ↓ 0.16% |
Total Liabilities | 33.2B | ↓ 1.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 87.7B | ↑ 3.34% |
Total Liabilities | 35.3B | ↑ 6.45% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 84.5B | ↓ 3.7% |
Total Liabilities | 31.0B | ↓ 12.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 83.4B | ↓ 1.29% |
Total Liabilities | 30.0B | ↓ 3.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 78.6B | ↓ 5.81% |
Total Liabilities | 28.7B | ↓ 4.35% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.0B | ↑ 15.65% |
Investing Cash Flow | -2.9B | ↑ 249.7% |
Financing Cash Flow | -797.0M | ↓ 74.28% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.0B | ↓ 1.75% |
Investing Cash Flow | -1.2B | ↓ 58.02% |
Financing Cash Flow | 16.4B | ↓ 2153.44% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.2B | ↑ 57.1% |
Investing Cash Flow | -21.2B | ↑ 1615.45% |
Financing Cash Flow | 1.0B | ↓ 93.85% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↑ 34.63% |
Investing Cash Flow | -13.0B | ↓ 38.85% |
Financing Cash Flow | 1.3B | ↑ 28.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.5B | ↑ 1.93% |
Investing Cash Flow | -2.2B | ↓ 82.8% |
Financing Cash Flow | -2.6B | ↓ 298.46% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 23.38% |
Investing Cash Flow | -304.0M | ↓ 86.39% |
Financing Cash Flow | -262.0M | ↓ 71.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 1.08% |
Investing Cash Flow | -431.0M | ↑ 41.78% |
Financing Cash Flow | -208.0M | ↓ 20.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↓ 13.19% |
Investing Cash Flow | -1.1B | ↑ 146.87% |
Financing Cash Flow | 2.4B | ↓ 1274.52% |
Sell
Neutral
Buy
Danaher Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Danaher Corp.
Revenue is down for the last 2 quarters, 5.79B → 5.74B (in $), with an average decrease of 0.9% per quarter
Netprofit is down for the last 2 quarters, 1.08B → 907.0M (in $), with an average decrease of 16.6% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 3.1%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Wellington Management Company LLP
FMR Inc
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Danaher Corp. has declared dividend of $0.27
Read MoreDanaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.
Organization | Danaher Corp. |
Employees | 61000 |
CEO | Mr. Steven M. Rales |
Industry | Health Technology |